Maintenance of remission with 6-week interval of tocilizumab in RA patients who have been in remissio
Phase 4
- Conditions
- rheumatoid arthritis
- Registration Number
- JPRN-UMIN000015482
- Lead Sponsor
- Department of Rheumatology & Clinical Immunology Saitama Medical Center, Saitama Medical Universitity
- Brief Summary
25 cases were enrolled
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have taken more than 5 mg/day of prednisolone
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method remission rate at 1 year after 6-week interval of tocilizumab therapy (DAS28-ESR &/or SDAI)
- Secondary Outcome Measures
Name Time Method